Td Asset Management Inc Moon Lake Immunotherapeutics Transaction History

Td Asset Management Inc

$102 Billion
Q1 2025

A detailed history of Td Asset Management Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Td Asset Management Inc holds 216,904 shares of MLTX stock, worth $10.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

216,904

Previous 261,634 17.1%

Holding current value

$10.5 Million

Previous $13.9 Million 39.05%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$36.75 - $54.34 $1.64 Million - $2.43 Million	-44,730 Reduced 17.1%	216,904 $8.47 Million
Q4 2024 Feb 11, 2025	BUY	$45.84 - $57.91 $2.1 Million - $2.65 Million	45,800 Added 21.22%	261,634 $13.9 Million
Q3 2024 Nov 01, 2024	BUY	$40.15 - $55.4 $264,990 - $365,640	6,600 Added 3.15%	215,834 $10.9 Million
Q2 2024 Aug 02, 2024	BUY	$38.43 - $48.6 $197,530 - $249,804	5,140 Added 2.52%	209,234 $9.2 Million
Q1 2024 May 08, 2024	SELL	$43.78 - $63.86 $221,001 - $322,365	-5,048 Reduced 2.41%	204,094 $10.3 Million
Q4 2023 Feb 12, 2024	BUY	$36.35 - $63.02 $318,135 - $551,551	8,752 Added 4.37%	209,142 $12.6 Million
Q3 2023 Oct 27, 2023	BUY	$48.35 - $61.26 $4.87 Million - $6.17 Million	100,750 Added 101.11%	200,390 $11.4 Million
Q2 2023 Aug 09, 2023	BUY	$19.01 - $51.79 $614,555 - $1.67 Million	32,328 Added 48.03%	99,640 $5.08 Million
Q3 2022 Nov 07, 2022	BUY	$5.25 - $9.27 $201,316 - $355,467	38,346 Added 132.38%	67,312 $538,000
Q2 2022 Aug 04, 2022	BUY	$4.69 - $13.25 $135,850 - $383,799	28,966 New	28,966 $152,000

Others Institutions Holding MLTX

# of Institutions

161

Shares Held

55.3M

Call Options Held

481K

Put Options Held

229K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.79B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Moon Lake Immunotherapeutics Transaction History